Edwards Lifesciences carries best-in-class margins and a consistent earnings beat pattern, but a forward multiple of 25.6x combined with price momentum below the acceptable threshold, a 74% product concentration in a single franchise, and only about 1% headroom to the near-term price target create a risk/reward profile that does not justify adding to the position at current levels.
Thesis pillars
- Best In Class Margins Quality↑Improving
- Single Product Concentration Risk↓Deteriorating
- Rich Valuation Weak Momentum↑Improving
- +1 more pillar — see the Why tab for full reasoning
Edwards Lifesciences Corporatio (EW) Stock Analysis
Oversold Bounce setup · Temporary headwind edge
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $82.63, but acceptable to hold if already in. Reasons: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%).
Edwards Lifesciences designs and manufactures structural heart devices across three lines — TAVR (74% of 2025 net sales), TMTT (9%), and Surgical (17%) — sold through direct sales forces in approximately 100 countries. The U.S. accounted for 58% of 2025 net sales; no single... Read more
Hold if already holding. Not a fresh buy at $82.63, but acceptable to hold if already in. Reasons: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%). Chart setup: Oversold RSI 9, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, news boost earnings 0.70, news boost analyst 0.70, earnings proximity 96d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
About Edwards Lifesciences Corporatio
About Edwards Lifesciences Corporatio
Edwards Lifesciences generated net sales across three structural heart device platforms in 2025: TAVR — led by the SAPIEN family, which has treated over 1.2 million patients since commercial launch in Europe in 2007 — contributed 74% of net sales; TMTT contributed 9%; and Surgical contributed 17%. The U.S. accounted for 58% of 2025 net sales, with international markets in Europe, Japan, and Rest of World comprising the remaining 42%. Research and development spending represented approximately 18% of 2025 sales.
Edwards Lifesciences earns revenue through direct sales forces in approximately 100 countries and, in some markets, through independent distributors and consignment arrangements. TAVR products including the SAPIEN 3 platform are sold to hospitals and health systems that obtain reimbursement from government programs, private insurance, and managed care. Primary competitors in TAVR and Surgical include Medtronic plc and Abbott Laboratories; in TMTT, Abbott is the primary competitor. Manufacturing is conducted at facilities in the United States, Singapore, Costa Rica, and Ireland. The company purchases certain supplies from single sources due to sole-source availability or regulatory constraints; finding alternative qualified suppliers may require significant effort given FDA validation requirements. R&D programs include ongoing clinical trials for TAVR indication expansion, TMTT (PASCAL, EVOQUE, SAPIEN M3), and Surgical platforms.
Show full overview
Edwards Lifesciences manufactures products at overseas facilities in Singapore, Costa Rica, and Ireland while facing potential tariff exposure from the U.S. Department of Commerce's Section 232 investigation into medical device imports under the Trade Expansion Act of 1962. If tariffs are imposed on components or finished goods from these facilities, manufacturing costs could rise, and sourcing alternatives may be time-consuming given FDA regulatory validation requirements for replacement suppliers. This exposure — concentrated foreign manufacturing combined with single-source supply relationships — exposes the company to cost and supply disruption risk that would be difficult to remediate quickly.
See also: Healthcare · Medical Devices
From Edwards Lifesciences Corporatio's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-26Recent Developments — Edwards Lifesciences Corporatio
Latest news
- NEWS EW (Edwards Lifesciences Corporation) reports Q4 2025 EPS miss, shares climb 2.45 percent amid positive investor sentime — Cổng thông tin điện tử Tỉnh Sơn La negative
- NEWS Universal Beteiligungs und Servicegesellschaft mbH Acquires 21,165 Shares of Edwards Lifesciences Corporation $EW - Mark — MarketBeat neutral
- NEWS A Look at Edwards Lifesciences Corp (EW) After 3.1% Decline -- G - GuruFocus — GuruFocus negative
- NEWS Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch — MarketWatch negative
- NEWS Mizuho Adjusts Price Target on Edwards Lifesciences to $105 From $100, Maintains Outperform Rating - marketscreener.com — marketscreener.com positive
Generated 2026-07-26T09:17:40Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductTAVR74%10-K Item 1: 'Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively.'
- HIGHGeographicUnited States58%10-K Item 1: 'In 2025, 58% of our net sales were derived from sales to customers in the United States.'
- HIGHSuppliersingle-source supplies10-K Item 1: 'we purchase certain supplies from single sources for reasons of sole source availability or constraints resulting from regulatory requirements'
Material Events(8-K, last 90d)
- 2026-05-04Item 5.02MEDIUMTheodora Mistras appointed Corporate VP and CFO effective May 29, 2026, succeeding Scott B. Ullem. Mistras previously served as CFO of Viatris, Inc. since March 2024. No reason cited for Ullem's departure.SEC filing →
- 2026-05-08Item 5.02LOWStockholders approved Amended and Restated Long-Term Stock Incentive Compensation Program at May 7, 2026 Annual Meeting, increasing available shares by 7,000,000 to a total of 341,500,000. Routine compensatory arrangement; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $82.63, but acceptable to hold if already in. Reasons: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%). Chart setup: Oversold RSI 9, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Target $90.32 (+9.3%), stop $80.05 (−3.2%), A.R:R 1.5:1. Score 5.9/10, moderate confidence.
Take-profit target: $90.32 (+9.3% upside). Target $90.32 (+9.3%), stop $80.05 (−3.2%), A.R:R 1.5:1. Stop-loss: $80.05.
Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%); Thin upside margin: 9.3%.
Edwards Lifesciences Corporatio trades at a P/E of 49.2 (forward 24.6). TrendMatrix value score: 4.7/10. Verdict: Hold.
42 analysts cover EW with a consensus score of 4.0/5. Average price target: $100.
What does Edwards Lifesciences Corporatio do?Edwards Lifesciences designs and manufactures structural heart devices across three lines — TAVR (74% of 2025 net...
Edwards Lifesciences designs and manufactures structural heart devices across three lines — TAVR (74% of 2025 net sales), TMTT (9%), and Surgical (17%) — sold through direct sales forces in approximately 100 countries. The U.S. accounted for 58% of 2025 net sales; no single customer exceeded 10%. Primary competitors include Medtronic and Abbott, and R&D spending represented approximately 18% of 2025 sales.